Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for...

Journal for ImmunoTherapy of Cancer 2020 / 05 Vol. 8; Iss. 1

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Xie, Lu, Xu, Jie, Sun, Xin, Guo, Wei, Gu, Jin, Liu, Kuisheng, Zheng, Bingxin, Ren, Tingting, Huang, Yi, Tang, Xiaodong, Yan, Taiqiang, Yang, Rongli, Sun, Kunkun, Shen, Danhua, Li, Yuan
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
8
Journal:
Journal for ImmunoTherapy of Cancer
DOI:
10.1136/jitc-2020-000798
Date:
May, 2020
File:
PDF, 561 KB
2020
Conversion to is in progress
Conversion to is failed